

Dec 30, 2020

**Editor-in-Chief,**  
*World Journal of Clinical Oncology*

Resubmission of Manuscript: NO. 60254 (Revised)

Dear Sir,

Enclosed please find the revised manuscript entitled “A review of 10 years of research on breast cancer patients: focus on indoleamine 2,3-dioxygenase” (Manuscript: NO. 60254 ) and our responses to the reviewers and editor comments. We appreciate the time and details provided by each reviewer and by you, which enabled us to improve the manuscript.

We hope the revised manuscript is now acceptable for publication in *World Journal of Clinical Oncology*.

We appreciate your consideration of our manuscript.

Yours sincerely

**Dr. Kashif Asghar (PhD)**

Research Scientist, Basic Sciences Research,  
Shaukat Khanum Memorial Cancer Hospital & Research Centre  
7A Block R-3 M.A. Johar Town, Lahore, Punjab, 54000, Pakistan  
Adjunct Faculty, Department of Pharmacology University of Health Sciences, Lahore  
Phone: +92-42-35905000 Ext: 4365  
[www.shaukatkhanum.org.pk](http://www.shaukatkhanum.org.pk)

## Point-by-point response

Q1: The manuscript must be subjected to an extended English revision.

Ans: We have revised the manuscript as suggested.

Q2: The authors must present the content of the review separated according to different sub-themes under subtitles (e.g. IDO expression in breast cancer subtypes, IDO as a prognostic marker, etc.). Take examples of other reviews.

Ans: The revised manuscript has different subthemes as per suggestion.

1. IDO impact on breast cancer patients
2. IDO in triple negative breast cancer
3. Therapeutic and prognostic significance of IDO
4. Future prospects

Q3: Clinical trials must be cited (e.g. phase II clinical trial IDO inhibitor (1-Methyl-Tryptophan;1-MT) is used to treat the metastatic breast cancer patients).

Ans: We have elaborated this information in “Future prospects” section with reference.

Q4: Revise the papers cited, the authors must be accurate to what is written in the original paper (e.g. The authors: “Lyon et al. observed high tryptophan degradation in early stage breast cancer along with neuropsychiatric symptoms[22]. Lyon et al. wrote: Given the multifactorial role of IDO and TRP, further research is necessary to determine the relationships among these important biological factors and neuropsychiatric symptoms, treatment efficacy, prognosis, and recurrence in women with BCA.

Ans: We have revised the manuscript keeping in view the suggestion of the reviewer (e.g. “A similar study conducted by Lyon et al. to compare levels of tryptophan degradation in women with or without breast cancer and observed an increased Kyn/Trp ratio in women with breast cancer. Keeping in view the multifactorial role of IDO, they suggested that further research was necessary to determine the relationships among these important biological factors and neuro-psychiatric symptoms in women with breast cancer”)

Q5: The authors must write the review in a fluently manner. Must connect between sentences of the same subject and pay attention to the contradictory function of IDO during the literature.

Ans: We have revised as suggested.

Furthermore, we have arranged the references according to the journal requirement.

The revised manuscript has been attached.